MEET YOUR MATCH 2020

Participants in the BioBusiness Summer School get the opportunity to learn more about specific positions and organisations within the industry during 45-minute Meet your Match sessions. We have selected the following professionals for this years' Meet your Match:

Round 1:
- Bauke Anninga, Associate M Ventures
- Riemke van Dijkhuizen-Radersma, Genmab

Round 2:
- Marco Timmers, CEO Synthon Biopharmaceuticals
- Pim van Hee, Innovation Manager DSM

Round 1 _ 14:00 - 14:45 hours

Bauke Anninga

Bauke Anninga
Associate, M Ventures
Bauke Anninga, PhD, joined M Ventures in September 2019 and is currently an Associate in the Healthcare team. Before joining M Ventures, Bauke worked at Jefferies International for two years in the Healthcare Investment Banking group in London (UK). During his time at Jefferies he advised on several financings and M&A transactions across the biotechnology, pharmaceutical and medical devices sectors. Before that, he was involved in a boutique life-science investment sourcing and due diligence company in Cambridge (UK). He also co-founded the Innovation Forum (UK), which is a global network and accelerator for science-based ventures. Bauke has a PhD in Cancer Studies from King’s College London (UK) and an MSc in Technical Medicine from the University of Twente (The Netherlands).

Riemke van Dijkhuizen-Radersma

Riemke van Dijkhuizen-Radersma
Vice President Project & Portfolio Management, Genmab
Riemke van Dijkhuizen-Radersma is Vice President Project & Portfolio Management at Genmab BV (Utrecht, The Netherlands), an international biotech company focusing on the discovery and development of antibody based therapies for the treatment of cancer. She oversees the project management activities supporting product discovery, preclinical and clinical development. Together with her team, she is leading multidisciplinary Compound Development Teams to develop and execute drug development plans. Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies.

Before joining Genmab in 2008, she has worked for over 10 years in several life sciences companies varying from small start up biotech to big pharma companies.

Riemke received her master’s degree (1997) and PhD degree (2004) in Chemical Engineering from the University of Twente (The Netherlands).

Round 2 _ 15:00 - 15:45 hours

Marco TimmersMarco Timmers
CEO,
Synthon Biopharmaceuticals
Marco was appointed Chief Executive Officer of Synthon Biopharmaceuticals in November 2019. In his previous role as Chief Scientific Officer he was responsible for the development of a pipeline of New Molecular Entities (New Biological Entities & New Chemical Entities), including monoclonal antibodies, antibody-drug conjugates and small molecules. Synthon Biopharmaceuticals is a clinical stage pharma company focusing on the development of innovative precision medicines in oncology and (auto-)immune diseases. The company is based in Nijmegen (NL) and currently employs around 375 staff, the majority being MSc and PhD. Synthon Biopharmaceuticals is in the top-15 of R&D companies in NL and in the top-3 of Life Sciences R&D companies in NL, with an annual R&D budget of over 80 million Euros. For more information: www.synthonbiopharmaceuticals.com

Before joining Synthon Biopharmaceuticals early 2012, Marco worked at Organon/Schering-Plough/MSD for over 15 years, where he held positions of increasing responsibility, lastly as Head of Medicinal Chemistry, Proof-of-Concept Leader (up to Phase II clinical studies) and Head of Pharmacology (Endocrinology & Endocrinological Oncology). Marco was also a member of the Organon, Schering-Plough & MSD R&D management teams in NL.

Marco holds a PhD (1997) in Bio-Organic Chemistry (cum laude) from Leiden University, The Netherlands. His key competencies are: project management, (medicinal) chemistry, pharmacology, pharmaceutical R&D, antibody technology, oncology, endocrinology, antibody-drug-conjugates, clinical development, human resource management, coaching of multidisciplinary teams, innovation management, inspirational skills, change management.

Pim van Hee

Pim van Hee
Innovation Manager, DSM
Pim van Hee has an MSc from Wageningen University in Biotechnology, and a PhD from Delft University of Technology in Bioprocess Technology. He has worked for the past 15 years at DSM in various roles at DSM, starting as R&D Scientist focusing on product and process development of food ingredients, such as enzymes and starter cultures. Then via roles of R&D Project manager, and Manufacturing Project Manager, he moved into the role of Innovation Manager.

As Innovation Manager he is responsible for managing the innovation portfolio for specific market segments. Current focus is dairy and plant-based food.

Prescilla Jeurink
Scientific Consultant, D2BScience
Prescilla started her scientific education in Experimental Zoology and Biotechnology at the Higher Laboratory Education in Utrecht, after which she worked for three years as a research technician at the Immunopharmacology group of the Utrecht University. Hereafter she worked in the Cell biology and Immunology group of the Wageningen University on a PhD project entitled “Mutual influence of consumption patterns on the development of food allergy”, funded by the Allergy Consortium Wageningen. After a 9 year-employment as a (senior) scientist within the Immunology team of Danone Nutricia Research, and 2 year-position as Cluster Leader Nutrition & Cell biology within FrieslandCampina, she currently provides Scientific Consultancy at D2BScience and will soon start as a part-time Pharmacology teacher at the Utrecht University.

Jumpstart your career

Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will take place from 28 June to 2 July 2021!

Why participate

The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.

Employers meet talent

Is your organisation interested in early-career talents in Life Sciences? BioBusiness Summer School can get you in touch with business oriented PhDs, postdocs or Master students. More info can be found here.